Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces that the underwriters of its offering of 6,400,000 American Depositary Shares (“ ADSs ”), each representing one ordinary share, €0.01 nominal value per share (each an “ Ordinary Share ”), of the Company, in the United States (the “ Offering ”) have exercised in full their option to purchase 960,000 additional ADSs (the “ Additional ADSs ”), representing 15% of the total number of ADSs initially sold in the Offering, pursuant to the 23rd resolution of the Company’s combined shareholders’ meeting held on May 11, 2026.

The Additional ADSs are expected to be delivered concurrently with the closing of the Offering, which is expected to close on July 6, 2026.

Following the exercise in full of the over-allotment option, the total number of ADSs issued in the Offering will amount to 7,360,000 ADSs, resulting in gross proceeds for the Company of approximately $920.0 million (€807.4 million) and estimated net proceeds, after deducting underwriting commissions and estimated offering expenses payable by the Company, of approximately $874.1 million (€767.1 million).

The Company intends to use the net proceeds from the Offering for: expenses relating to potential commercialization of the Company’s lead...